ERBB2 and breast cancer: lncRNA JPX recruits FTO on phosphoinositide‐dependent kinase‐1 (PDK1), which demethylates the transcript and protects it from degradation, resulting in enhanced glucose uptake and lactate production leading to temozolomide resistance.[86] Increased glycolysis due to GLUT4 overexpression is responsible for therapeutic resistance in HER2‐positive breast cancer.